Autolus Therapeutics (AUTL) Long-Term Deferred Tax (2019 - 2025)

Autolus Therapeutics (AUTL) has 7 years of Long-Term Deferred Tax data on file, last reported at $3.6 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Deferred Tax rose 9.91% year-over-year to $3.6 million; the trailing twelve-month figure through Dec 2025 stood at $3.6 million (up 9.91% YoY), and the FY2025 full-year result was $3.6 million, up 9.91% from the prior year.
• Long-Term Deferred Tax for Q4 2025 stood at $3.6 million, up from $2.4 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $3.6 million in Q4 2025 and bottomed at $1.4 million in Q3 2021.
• The 5-year median for Long-Term Deferred Tax is $2.4 million (2022), against an average of $2.5 million.
• The widest annual swing landed in 2021, when Long-Term Deferred Tax surged 396.1%; it then slipped 29.51% in 2025.
• A 5-year view of Long-Term Deferred Tax shows it stood at $1.8 million in 2021, then advanced by 13.69% to $2.1 million in 2022, then surged by 47.54% to $3.1 million in 2023, then rose by 5.75% to $3.2 million in 2024, then increased by 9.91% to $3.6 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $3.6 million (Q4 2025), $2.4 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.

Peer Comparison